Arctic Bioscience ASOSL:ABS -1.85%55 PB Ratio is 0.50 as of Jul. 11, 2026, which is 47% below its 10-year median of 0.94. GuruFocus rates OSL:ABS with a GF Score™ of 55/100 and a GF Value™ of kr10.62 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,227 Biotechnology companies, Arctic Bioscience AS ranks better than 94.95% on this metric.
The historical rank and industry rank for Arctic Bioscience AS's PB Ratio or its related term are showing as below:
OSL:ABS'
s PB Ratio Range Over the Past 10 Years
Min: 0.19 Med: 0.94 Max: 11.4
Current: 0.49
During the past 8 years, Arctic Bioscience AS's highest PB Ratio was 11.40. The lowest was 0.19. And the median was 0.94.
OSL:ABS's PB Ratio is ranked better than 94.95% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs OSL:ABS: 0.49
During the past 12 months, Arctic Bioscience AS's average Book Value Per Share Growth Rate was -22.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -18.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.80% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Arctic Bioscience AS was 144.60% per year. The lowest was -18.30% per year. And the median was 57.00% per year.
Back to Basics: PB Ratio
Arctic Bioscience AS (OSL:ABS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Arctic Bioscience AS PB Ratio Related Terms
Arctic Bioscience AS PB Ratio Historical Data
* Premium members only.
The historical data trend for Arctic Bioscience AS's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Arctic Bioscience AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arctic Bioscience AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Arctic Bioscience AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Arctic Bioscience AS (OSL:ABS) has a PB Ratio of 0.50 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Arctic Bioscience AS and its competitors. This is 47% below median its historical median of 0.94. Over the past decade, Arctic Bioscience AS's PB Ratio has ranged from 0.19 to 11.40. According to the industry distribution chart, Arctic Bioscience AS ranks #62 out of 1227 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Arctic Bioscience AS's PB Ratio too high?
Arctic Bioscience AS's current PB Ratio of 0.50 is 47% below median its 10-year median of 0.94. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 11.40. The Biotechnology industry median PB Ratio is 2.95. Arctic Bioscience AS's value of 0.50 is 83.1% below this industry median. Based on the distribution chart, Arctic Bioscience AS ranks #62 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arctic Bioscience AS has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arctic Bioscience AS's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arctic Bioscience AS ranks #62 out of 1227 companies for PB Ratio. This places Arctic Bioscience AS in the top 5% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.95. Arctic Bioscience AS's value of 0.50 is 83.1% below this benchmark. Historically, Arctic Bioscience AS's own PB Ratio has ranged from 0.19 to 11.40 over the past decade. While the company's 10-year median is 0.94 vs. the industry median of 2.95, Arctic Bioscience AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arctic Bioscience AS's current PB Ratio of 0.50 is 83.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Arctic Bioscience AS and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arctic Bioscience AS's current PB Ratio is 0.50, which is 47% below median its own 10-year median of 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arctic Bioscience AS stock overvalued right now?
Based on GuruFocus' analysis, Arctic Bioscience AS (OSL:ABS) is currently considered Possible Value Trap. The stock's GF Value™ is kr10.62, compared to a current price of kr3.19 — trading 70% below its estimated fair value. The current PB Ratio is 0.50, which is 47% below median its 10-year median of 0.94 and 83.1% below the Biotechnology industry median of 2.95. Arctic Bioscience AS's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Arctic Bioscience AS (OSL:ABS), the current PB Ratio is 0.50 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arctic Bioscience AS (OSL:ABS) Overvalued in 2026?
Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued.
The current stock price of kr3.19 is trading 70% below its estimated GF Value™ of kr10.62.
GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.
Key valuation signals for OSL:ABS:
PB Ratio: 0.50 (47% below median its 10-year median of 0.94)
GF Value™: kr10.62 vs. price of kr3.19 (70% below fair value)
Industry Position: 83.1% below the Biotechnology median (#62 of 1227)
No single metric tells the full story. See the OSL:ABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
55GF Score
Get the complete analysis for OSL:ABS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ABS has been successfully added to your 
